HER2/NEU RECEPTOR ANTAGONIST
Margenza is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with metastatic HER2-positive breast cancer who have received two or more prior therapies. Margenza may also be referred to by its drug name, margetuximab-cmkb.
Margenza is a HER2/neu receptor antagonist. Margenza is believed to fight breast cancer by blocking cancer cells from receiving signals that would tell them to grow.
How do I take it?
Margenza is generally administered as an intravenous infusion every three weeks.
Margenza comes in the form of an injectable suspension.
The FDA-approved label for Margenza lists common side effects including fatigue, nausea, diarrhea, vomiting, constipation, headache, fever, hair loss, abdominal pain, nerve problems, chest pain, cough, decreased appetite, and pain in the arms and legs.
Rare but serious side effects listed for Margenza include heart problems, low white blood cell counts, pneumonia, infusion-related reactions, and potential fetal harm.
For more details about this treatment, visit:
Margenza — Macrogenics
Margenza — BreastCancer.org